Helex
Genomic medicines for kidney diseases with high unmet need
* Data source: Crunchbase
- Founded
- 2016
- Employees*
- 2-10
- Website
- www.helex.bio
"We call ourselves the GPS for gene editing, because we really decide on that exact location where the guide RNA can make the cut for a safer therapy, a more efficient therapy, so that there are no more unintended cuts anywhere else in the genome."
It costs $2 billion to develop a new gene-editing therapy, and $2 million simply to treat one patient.
Helex is taking the promise of non-viral targeted delivery and genome editing to the kidney, developing first-in-class genetic medicines for renal indications. Helex combines its proprietary kidney tropic lipid nanoparticle delivery system with the Epic-Cure™ 3D genome-based drug designer platform to create a robust renal franchise of precise and scalable therapeutics. Our lead asset is a mutation-agnostic, potential one-and-done therapy for Autosomal Dominant Polycystic Kidney Disease that impacts over 4 million people worldwide.
More Companies
